Biotoxtech, South Korea to Deploy Comprehensive Suite of Preclinical Study Management and SEND Software Solutions from Instem
Instem Technology Selected to Streamline Preclinical Operations, Improve Productivity and Ensure SEND Compliance at South Korea’s Largest Preclinical R&D Facility
CONSHOHOCKEN, PA – Business Wire, June 3, 2020 - Instem, a leading provider of IT solutions to the global life sciences market, announced today that South Korean Contract Research Organization (CRO), Biotoxtech Co., Ltd. (Biotoxtech) has purchased a comprehensive package of preclinical data collection, analysis and regulatory submissions management solutions to automate and optimize study related processes at its R&D facility in South Korea’s North Chungcheong Province.
April 29, 2020 - Instem Continues to Ramp up as Demand for Target Safety Assessment Service Reaches New Heights
March 3, 2020 - Provantis Selected to Improve Study Turnaround Times and Further Increase Data Quality at Pune Facility
November 15, 2019 - Instem’s Acquisition of Leadscope, Inc. is Another Step in its Mission to Help Clients Bring Life Enhancing Products to Market Faster
November 13, 2019 - Instem Continues Powerful Presentation Series Focusing on Their Use of Artificial and Augmented Intelligence Techniques to Improve Drug Development Processes